HomeCompareSMMCF vs ABBV

SMMCF vs ABBV: Dividend Comparison 2026

SMMCF yields 24.05% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $10.4K in total portfolio value· pulled ahead in Year 10
10 years
SMMCF
SMMCF
● Live price
24.05%
Share price
$17.27
Annual div
$4.15
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$93.3K
Annual income
$10,170.36
Full SMMCF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — SMMCF vs ABBV

📍 ABBV pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMMCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMMCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMMCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMMCF
Annual income on $10K today (after 15% tax)
$2,044.59/yr
After 10yr DRIP, annual income (after tax)
$8,644.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $12,881.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMMCF + ABBV for your $10,000?

SMMCF: 50%ABBV: 50%
100% ABBV50/50100% SMMCF
Portfolio after 10yr
$98.5K
Annual income
$17,747.57/yr
Blended yield
18.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SMMCF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMMCF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMMCFABBV
Forward yield24.05%3.09%
Annual dividend / share$4.15$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$93.3K$103.7K
Annual income after 10y$10,170.36$25,324.79
Total dividends collected$58.1K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMMCF vs ABBV ($10,000, DRIP)

YearSMMCF PortfolioSMMCF Income/yrABBV PortfolioABBV Income/yrGap
1$13,105$2,405.40$11,555$434.96+$1.6KSMMCF
2$16,969$2,946.15$13,485$635.47+$3.5KSMMCF
3$21,722$3,565.12$15,933$937.67+$5.8KSMMCF
4$27,508$4,265.15$19,118$1,400.80+$8.4KSMMCF
5$34,481$5,047.83$23,384$2,125.24+$11.1KSMMCF
6$42,808$5,913.54$29,290$3,286.81+$13.5KSMMCF
7$52,666$6,861.38$37,776$5,205.38+$14.9KSMMCF
8$64,242$7,889.19$50,495$8,488.44+$13.7KSMMCF
9$77,732$8,993.65$70,497$14,346.44+$7.2KSMMCF
10← crossover$93,344$10,170.36$103,718$25,324.79$10.4KABBV

SMMCF vs ABBV: Complete Analysis 2026

SMMCFStock

Summit Industrial Income REIT is an unincorporated open-end REIT focused on growing and managing a portfolio of light industrial and other properties across Canada. Summit II's units are listed on the TSX and trade under the symbol SMU.UN.

Full SMMCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SMMCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMMCF vs SCHDSMMCF vs JEPISMMCF vs OSMMCF vs KOSMMCF vs MAINSMMCF vs JNJSMMCF vs MRKSMMCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.